Kalvista Pharmaceuticals, INC Form 4 insider transactions

KalVista Pharmaceuticals' Chief Commercial Officer, Nicole Sweeny, sold 3,975 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

KalVista Pharmaceuticals CFO Brian Piekos reported the acquisition of 5,000 shares from RSU vesting and the subsequent sale of 1,767 shares to cover tax withholding obligations.

KalVista Pharmaceuticals' CEO, Benjamin L. Palleiko, reported the acquisition of shares from RSU vesting and a subsequent sale to cover tax withholding obligations.

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, sold 1,163 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, reported the acquisition of 1,774 shares from RSU settlement and the sale of 1,109 shares to cover tax obligations.

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported the acquisition of common stock through RSU settlement and a subsequent sale to cover tax withholding obligations.

KalVista Pharmaceuticals' Chief Operations Officer, Bilal Arif, was granted 49,000 Restricted Stock Units, vesting quarterly starting May 22, 2026.

KalVista Pharmaceuticals' Chief Commercial Officer, Nicole Sweeny, was granted 100,000 Restricted Stock Units, vesting quarterly starting May 22, 2026.

KalVista Pharmaceuticals' CFO, Brian Piekos, was granted 100,000 restricted stock units, vesting quarterly starting May 22, 2026.

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, was granted 100,000 restricted stock units, vesting quarterly starting May 22, 2026.

KalVista Pharmaceuticals' CEO, Benjamin L. Palleiko, was granted 325,000 restricted stock units, vesting quarterly starting May 22, 2026.

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported future transactions under a Rule 10b5-1 plan, including RSU vesting and a subsequent stock sale for tax obligations.

KalVista Pharmaceuticals' Chief Commercial Officer, Nicole Sweeny, reported the acquisition of common stock through RSU vesting and a subsequent sale to cover tax withholding obligations.

KalVista Pharmaceuticals' CFO, Brian Piekos, sold 4,471 shares of common stock to cover tax obligations following the vesting of 15,000 restricted stock units.

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, reported the vesting of restricted stock units and a subsequent 'sell to cover' transaction for tax obligations.

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported the acquisition of shares from RSU vesting and a subsequent sale to cover tax withholding obligations.

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, exercised 87,390 employee stock options, acquiring common stock.

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported the acquisition of shares from RSU settlements and a subsequent sale to cover tax withholding obligations.

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, reported the sale of 2,683 common shares to cover tax withholding obligations related to restricted stock unit vesting.

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, sold 3,075 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

KalVista Pharmaceuticals CEO Benjamin Palleiko reported the acquisition of common stock from RSU vesting and a subsequent sale to cover tax withholding obligations.

KalVista Pharmaceuticals' Chief Operations Officer, Bilal Arif, was granted 100,000 stock options with an exercise price of $11.49.

KalVista Pharmaceuticals Director Brian JG Pereira was granted 30,000 stock options with an exercise price of $12.05, vesting over 12 months.

KalVista Pharmaceuticals Director Nancy Stuart was granted 30,000 stock options with an exercise price of $12.05, vesting over 12 months.

KalVista Pharmaceuticals Director Patrick Treanor was granted 30,000 stock options with an exercise price of $12.05, vesting over 12 months.

KalVista Pharmaceuticals, Inc. Director William Fairey was granted 30,000 stock options with an exercise price of $12.05, vesting over 12 months.

KalVista Pharmaceuticals Director Edward W. Unkart was granted 30,000 stock options with an exercise price of $12.05, vesting over 12 months.

KalVista Pharmaceuticals, Inc. Director Bethany Sensenig was granted 45,000 stock options with an exercise price of $12.05, vesting over three years.

KalVista Pharmaceuticals' CEO, Benjamin L. Palleiko, sold 7,294 shares of common stock at $15.84 per share to cover tax withholding obligations related to RSU vesting.